The DDX19B antibody is a polyclonal or monoclonal reagent designed to detect and study the DEAD-box RNA helicase DDX19B protein. DDX19B is a key regulator of mRNA export, translation termination, and nonsense-mediated mRNA decay (NMD). Its role in cellular processes such as nuclear export of viral RNAs and interaction with translation initiation factors has made it a focal point in molecular biology and virology research.
The antibody is primarily used in Western blot (WB), immunoprecipitation (IP), and immunocytochemistry (ICC) applications. This article synthesizes data from diverse sources to provide a detailed analysis of its technical specifications, research applications, and key findings.
| Application | Dilution |
|---|---|
| Western Blot | 1:500–1:3000 |
| Immunoprecipitation | 0.5–4.0 µg/1–3 mg lysate |
| ELISA | Varied (optimize per assay) |
The DDX19B antibody has been instrumental in studying its role in mRNA export. For instance, in influenza A virus (IAV) replication, DDX19B facilitates the nuclear export of viral RNAs, as shown by its depletion leading to delayed viral protein synthesis . Rescue experiments with RNA-binding defective mutants (e.g., R372G, R428Q) confirmed that RNA-binding activity is critical for this process .
CTIF Interaction: DDX19B binds CTIF (CBC-dependent translation initiation factor) to restrict translation initiation to the perinuclear region. Disruption of this interaction via mutations (e.g., F460A) causes uncontrolled cytoplasmic translation and NMD dysregulation .
Translation Termination: DDX19B stabilizes ribosomal complexes with eRF1 (eukaryotic release factor 1), enhancing peptide release during termination .
DDX19B inhibits NMD by modulating CTIF activity on CBC-bound mRNAs. Overexpression of CTIF mutants lacking DDX19B binding (e.g., F460A) increases NMD efficiency, as observed in globin and GPx1 reporter assays .